Hanlon AL - Search Results

1

The relationship of increasing radiotherapy dose to reduced distant metastases and mortality in men with prostate cancer.

Jacob R, Hanlon AL, Horwitz EM, Movsas B, Uzzo RG, Pollack A. Jacob R, et al. Among authors: hanlon al. Cancer. 2004 Feb 1;100(3):538-43. doi: 10.1002/cncr.11927. Cancer. 2004. PMID: 14745870 Free article.

2

Radiation therapy dose escalation for prostate cancer: a rationale for IMRT.

Pollack A, Hanlon A, Horwitz EM, Feigenberg S, Uzzo RG, Price RA. Pollack A, et al. World J Urol. 2003 Sep;21(4):200-8. doi: 10.1007/s00345-003-0356-x. Epub 2003 Sep 5. World J Urol. 2003. PMID: 12961097 Review.

3

Does age matter in the selection of treatment for men with early-stage prostate cancer?

Konski A, Eisenberg D, Horwitz E, Hanlon A, Pollack A, Hanks G. Konski A, et al. Cancer. 2006 Jun 15;106(12):2598-602. doi: 10.1002/cncr.21923. Cancer. 2006. PMID: 16683224 Free article.

4

Prostate-specific antigen nadir within 12 months of prostate cancer radiotherapy predicts metastasis and death.

Alcantara P, Hanlon A, Buyyounouski MK, Horwitz EM, Pollack A. Alcantara P, et al. Cancer. 2007 Jan 1;109(1):41-7. doi: 10.1002/cncr.22341. Cancer. 2007. PMID: 17133416 Free PMC article.

5

Relationship between prostate volume, prostate-specific antigen nadir, and biochemical control.

Kaminski JM, Hanlon AL, Horwitz EM, Pinover WH, Mitra RK, Hanks GE. Kaminski JM, et al. Among authors: hanlon al. Int J Radiat Oncol Biol Phys. 2002 Mar 15;52(4):888-92. doi: 10.1016/s0360-3016(01)02764-x. Int J Radiat Oncol Biol Phys. 2002. PMID: 11958880

6

Dose response in prostate cancer with 8-12 years' follow-up.

Hanks GE, Hanlon AL, Epstein B, Horwitz EM. Hanks GE, et al. Among authors: hanlon al. Int J Radiat Oncol Biol Phys. 2002 Oct 1;54(2):427-35. doi: 10.1016/s0360-3016(02)02954-1. Int J Radiat Oncol Biol Phys. 2002. PMID: 12243818

7

Hypoxic prostate/muscle pO2 ratio predicts for biochemical failure in patients with prostate cancer: preliminary findings.

Movsas B, Chapman JD, Hanlon AL, Horwitz EM, Greenberg RE, Stobbe C, Hanks GE, Pollack A. Movsas B, et al. Among authors: hanlon al. Urology. 2002 Oct;60(4):634-9. doi: 10.1016/s0090-4295(02)01858-7. Urology. 2002. PMID: 12385924

8

Validation of a treatment policy for patients with prostate specific antigen failure after three-dimensional conformal prostate radiation therapy.

Pinover WH, Horwitz EM, Hanlon AL, Uzzo RG, Hanks GE. Pinover WH, et al. Among authors: hanlon al. Cancer. 2003 Feb 15;97(4):1127-33. doi: 10.1002/cncr.11166. Cancer. 2003. PMID: 12569615 Free article.

9

Mindless or mindful? Radiation oncologists' perspectives on the evolution of prostate cancer treatment.

Pollack A, Horwitz EM, Movsas B, Hanlon AL. Pollack A, et al. Among authors: hanlon al. Urol Clin North Am. 2003 May;30(2):337-49, x. doi: 10.1016/s0094-0143(02)00177-5. Urol Clin North Am. 2003. PMID: 12735509 Review.

10

Modifying the American Society for Therapeutic Radiology and Oncology definition of biochemical failure to minimize the influence of backdating in patients with prostate cancer treated with 3-dimensional conformal radiation therapy alone.

Horwitz EM, Uzzo RG, Hanlon AL, Greenberg RE, Hanks GE, Pollack A. Horwitz EM, et al. Among authors: hanlon al. J Urol. 2003 Jun;169(6):2153-7; discussion 2157-9. doi: 10.1097/01.ju.0000067181.52741.09. J Urol. 2003. PMID: 12771738

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

391 results

Search Page

Filters